S241656

DRUG2 trials

Sponsors

Institut de Recherches Internationales Servier, Servier

Conditions

Acquired Resistance to KRAS G12C InhibitorAcute Myeloid LeukemiaBRAFBRAF Gene MutationBRAF Mutation-Related TumorsBRAF V600 MutationBRAF V600EBrain Metastases

Phase 1

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

RecruitingNCT05786924

Institut de Recherches Internationales ServierAcquired Resistance to KRAS G12C Inhibitor, BRAF, BRAF Gene Mutation +29

Start: 2023-04-18End: 2028-06-01Target: 554Updated: 2026-09-16

A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

Not yet recruitingNCT07719348

ServierAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome Acute Myeloid Leukemia

Start: 2026-09-15End: 2030-09-30Target: 64Updated: 2026-07-22

Related Papers

A phase 1/2, open-label study of oral S241656 (BDTX-4933) as monotherapy and in combination with other anti-cancer therapies in patients with KRAS, BRAF and other selected RAS/MAPK mutation positive malignancies.

Journal of Clinical Oncology2026-01-10

Abstract A090: Preclinical efficacy of BDTX-4933, a brain-penetrant, orthosteric RAF inhibitor, targeting oncogenic RAF conformation shared by groups of BRAF and upstream driver mutations

Molecular Cancer Therapeutics2023-12-01